Zostavax Gets Nod For Younger Age Group, But Supply Issues Make Sales Boost Unlikely
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck's ability to capitalize on FDA approval of the shingles vaccine in patients ages 50-59 years is questionable given ongoing supply constraints.